CRISPR-based gene editing revolutionized medicine—what's next for the firm that helped develop it?
CRISPR-Cas 9 is a gene-editing tool that made it possible to rewrite any organism's genetic code and tackle genetic diseases more effectively. Known as genetic scissors, CRISPR identifies a DNA ...
In a historic moment for gene editing, the U.S. late last year approved Casgevy, the first CRISPR-based therapy for sickle cell disease and beta thalassemia. One of the key figures behind the news was ...
May 12 (Reuters) - The University of California and the University of Vienna on Monday convinced a U.S. appeals court to revive their bid for patent rights to groundbreaking CRISPR gene-editing ...
DUBLIN--(BUSINESS WIRE)--ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, today announced ...
DUBLIN--(BUSINESS WIRE)--ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, today announced ...
At stake in the ongoing patent dispute over the gene-editing tool are rights to the most important new biotechnology of the age and credit for inventing it. The CRISPR patents are back in play. On ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results